IP Valuation for Organ Regeneration
This start-up had the twin purpose of seeking to save lives, while at the same time generating attractive returns for its investors. Core to its business was the aggregation of patents in this nascent technology space. Hence, the question was raised, which patents to aggregate and which patents not to pursue.
Oxfirst supported this company by helping it set up mechanisms to aggregate patents and systematically assessed the value of the patents, so to determine if they were appealing to the aggregator and what an adequate royalty rate for them would be.
The instruments provided to this firm helped them differentiate between commercially appealing IP and IP it should better stay away from.